Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

The Persistent Survival of MPN Cells to JAK2 Inhibition Is Dependent on SHP2 Activity, Which May Provide a Therapeutic Target to Enhance Current Anti-MPN Therapies

Garima Pandey, Guolin Zhang, Narmin Amin, Lucia Mazzacurati, Eric B. Haura, Gary W. Reuther, PhD

Blood (2018) 132 (Supplement 1): 3064.

https://doi.org/10.1182/blood-2018-99-118641

Published: 2018

Journal Articles

Targeting Insulin-like Growth Factor/Insulin Receptor Signaling to Overcome JAK2 Inhibitor Persistence in Myeloproliferative Neoplasms

Lucia Mazzacurati, Que T. Lambert, Gary W. Reuther, PhD

Blood (2017) 130 (Supplement 1): 2935.

https://doi.org/10.1182/blood.V130.Suppl_1.2935.2935

Published: 2017

Journal Articles

The Pan-PIM Inhibitor INCB053914 Displays Potent Synergy at Low Doses in Combination with Ruxolitinib in Pre-Clinical Models of MPNs

Lucia Mazzacurati, Que T. Lambert, Robert J. Collins, Holly K. Koblish, PhD, Bruce Ruggeri, Matthew C. Stubbs, Gary W. Reuther, PhD

Blood (2017) 130 (Supplement 1): 1661.

https://doi.org/10.1182/blood.V130.Suppl_1.1661.1661

Published: 2017

Journal Articles

Leukemogenic Cascade Induced by a Constitutively Active Neurotrophin Receptor, ΔTrkA.

Zhixiong Li, MD, Johann Meyer, PhD, Mathias Rhein, Olga Kustikova, PhD, Cornelia Rudolph, PhD, Kenji Kamino, MD, Thomas Neumann, Min Yang, BSc, Anke Wahlers, PhD, Boris Fehse, PhD, Gary W. Reuther, PhD, Brigitte Schlegelberger, MD, Arnold Ganser, MD, Christopher Baum, MD

Blood (2006) 108 (11): 1442.

https://doi.org/10.1182/blood.V108.11.1442.1442

Published: 2006

Journal Articles

Treatment with the Heat Shock Protein (hsp) 90 Inhibitor17-Dimethylaminoethylamino-17-Demethoxygeldanamycin (DMAG) Abrogates the Levels and Activity of the Receptor Tyrosine Kinase TrkA in Acute Leukemia Cells.

Sandhya Kumaraswamy, PhD, Que T. Lambert, MS, Kathy Rocha, BS, Purva Bali, MS, Warren Fiskus, PhD, Maria Balasis, BS, Michael Pranpat, MS, Sandhya Boyapalle, PhD, Alison Hannah, MD, Gary W. Reuther, PhD, Kapil Bhalla, MD

Blood (2005) 106 (11): 4401.

https://doi.org/10.1182/blood.V106.11.4401.4401

Published: 2005

NARROW

The Persistent Survival of MPN Cells to JAK2 Inhibition Is Dependent on SHP2 Activity, Which May Provide a Therapeutic Target to Enhance Current Anti-MPN Therapies

Targeting Insulin-like Growth Factor/Insulin Receptor Signaling to Overcome JAK2 Inhibitor Persistence in Myeloproliferative Neoplasms

The Pan-PIM Inhibitor INCB053914 Displays Potent Synergy at Low Doses in Combination with Ruxolitinib in Pre-Clinical Models of MPNs

Leukemogenic Cascade Induced by a Constitutively Active Neurotrophin Receptor, ΔTrkA.

Treatment with the Heat Shock Protein (hsp) 90 Inhibitor17-Dimethylaminoethylamino-17-Demethoxygeldanamycin (DMAG) Abrogates the Levels and Activity of the Receptor Tyrosine Kinase TrkA in Acute Leukemia Cells.

Email alerts

ASH Publications

American Society of Hematology

The Persistent Survival of MPN Cells to JAK2 Inhibition Is Dependent on SHP2 Activity, Which May Provide a Therapeutic Target to Enhance Current Anti-MPN Therapies

Targeting Insulin-like Growth Factor/Insulin Receptor Signaling to Overcome JAK2 Inhibitor Persistence in Myeloproliferative Neoplasms

The Pan-PIM Inhibitor INCB053914 Displays Potent Synergy at Low Doses in Combination with Ruxolitinib in Pre-Clinical Models of MPNs

Leukemogenic Cascade Induced by a Constitutively Active Neurotrophin Receptor, ΔTrkA.

Treatment with the Heat Shock Protein (hsp) 90 Inhibitor17-Dimethylaminoethylamino-17-Demethoxygeldanamycin (DMAG) Abrogates the Levels and Activity of the Receptor Tyrosine Kinase TrkA in Acute Leukemia Cells.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only